Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Can-Prevent-Lung
NCT04789681Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2021
- Primary completion
- Dec 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of canakinumab in lung cancer, sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2021; status: recruiting.
02
Drugs
canakinumab
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT04789681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04789681.